Filgotinib 200 mg (n=4) | Lanraplenib 30 mg (n=1) | |
24-hour urine protein in g/day, median change (% change) | −1.4 (−50.7) | −0.2 (−2.8) |
Spot UPCR in mg/mg, median change (% change) | −0.4 (−51.6) | −2.2 (−30.7) |
24-hour UPCR in mg/mg, median change (% change) | −0.7 (−45.5) | −4.4 (−52.0) |
eGFR in mL/min/1.73 m2, median change | −1.2 | −59.4 |
Partial remission, n (%) | 2 (50.0) | 0 (0.0) |
Complete remission, n (%) | 0 (0.0) | 0 (0.0) |
SELENA-SLEDAI total score, median change (% change) | 0.0 (0.0) | 4.0 (50.0) |
Physician global assessment score, median % change | −71.4 | 14.0 |
Patient global assessment score, median % change | −50.8 | −33.3 |
Anti-dsDNA in IU/mL, median change | 11.0 | 0.0 |
C3 complement component in mg/dL, median change | −19.3 | −17.7 |
C4 complement component in mg/dL, median change | −2.5 | −3.2 |
anti-dsDNA, anti-double-stranded DNA antibody; eGFR, estimated glomerular filtration rate; SELENA-SLEDAI, Safety of Estrogens in Lupus National Assessment-Systemic Lupus Erythematosus Disease Activity Index; UPCR, urine protein to creatinine ratio.